VD
Vivid Dx develops a next-generation diagnostic platform for rapid detection of sepsis-causing pathogens and antimicrobial resistance (AMR). The platform uses Raman spectroscopy and AI to deliver broad pathogen identification in 30 minutes and phenotypic AST results in three hours directly from blood. This accelerates actionable diagnostics, enabling faster targeted treatment for sepsis patients.
Updated 2 months ago
Funding
Funding not disclosed
Funding rounds are not available yet.
Founders
Founder details are not available yet.
Product
Features
- Vivid Dx develops a next-generation diagnostic platform for rapid detection of sepsis-causing pathogens and antimicrobial resistance (AMR). The platform uses Raman spectroscopy and AI to deliver broad pathogen identification in 30 minutes and phenotypic AST results in three hours directly from blood. This accelerates actionable diagnostics, enabling faster targeted treatment for sepsis patients.